Aerpio Pharms

ARPO NASDAQ
0.6600
+0.0200
+3.13%
Closed 16:00 08/20 EDT
Open
0.6300
Prev Close
0.6400
High
0.6600
Low
0.6300
Volume
84.59K
Avg Vol (3M)
113.05K
52 Week High
4.250
52 Week Low
0.6100
% Turnover
0.21%
Market Cap
26.38M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Aerpio Pharms ARPO stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.
MORE >

Recently

Name
Price
%Change